This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of Objective Response Rate
Timeframe: From enrollment until study completion, assessed up to 38 months
Assessment of Disease control rate
Timeframe: From enrollment until study completion, assessed up to 38 months
Assessment of Duration of Response
Timeframe: From enrollment until study completion, assessed up to 38 months
Assessment of Progression Free Survival
Timeframe: From enrollment until study completion, assessed up to 38 months
Evaluation of Safety by assessment of QTc prolongations
Timeframe: From enrollment until study completion, assessed up to 38 months
Evaluation of Safety by assessment of Adverse Events
Timeframe: From enrollment until study completion, assessed up to 38 months
Evaluation of Safety by assessment of vital signs
Timeframe: From enrollment until study completion, assessed up to 38 months
Evaluation of Safety by assessment of laboratory data
Timeframe: From enrollment until study completion, assessed up to 38 months